Jci_page_head_homepage_01 Jci_page_head_homepage_02
Evan D. Muse, Tony K.T. Lam, Philipp E. Scherer, Luciano Rossetti
Published in Volume 117, Issue 6
J Clin Invest. 2007; 117(6):1670–1678 doi:10.1172/JCI30440
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 2
Central resistin increased hepatic glucoses fluxes predominantly via glycogenolytic pathways.

(A and B) icv or IH infusion of resistin (black bars) resulted in 2- to 3-fold increases in hepatic flux through G6Pase (A) and glucose cycling (B) compared with vehicle (white bars). (C and D) Increased hepatic glucose fluxes were mainly accounted for by an increased rate of glycogenolysis (D) rather than gluconeogenesis (C). (E) Quantitative real-time RT-PCR revealed that central resistin had no effect on the hepatic expression of the key gluconeogenic enzymes PEPCK and G6Pase. (F) Decreased levels of p-AMPKα were apparent in the livers of resistin-treated animals as analyzed by immunoblot. *P < 0.05 compared with vehicle.